Abstract
This report describes an error in the Framingham Risk Score data presented in the original SPRINT publication. The data, presented in Table 1 of the main SPRINT publication in the New England Journal of Medicine and made available to SPRINT Challenge participants, incorrectly calculated the level of baseline cardiovascular risk of the study participants using the Framingham Risk Score. The correct calculation increased the number of participants identified as having >=15% 10-year risk from 5737 to 7089, a change from 61% to 76% of the total study population. This information is important for researchers attempting to validate and extend the trial findings and is particularly germane because the recently released American Heart Association/American College of Cardiology blood pressure guidelines changed blood pressure targets for pharmacologic therapy only for high-risk individuals. Clinical trial registration ID #NCT01206062.
